CA-NEXON-AMERICA
17.3.2021 16:02:05 CET | Business Wire | Press release
The Maestro, a brilliant tactician wielding both a sword and a pistol, joins Nexon’s MMORPG cross-platform marvel V4 today as its third new class along with new gear and various limited-time reward events, including one special for Amazon Prime members.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005156/en/
A melody crafted through blade and gun, the Maestro is the third class to join V4 since launch. The Maestro uses an enchanted sword and pistol to dole out ranged damage, leading the battle with a variety of brilliant techniques. Equipped with the Rapier main weapon and Magishot sub weapon, he can further shake up combat by switching between Indignant and Composed stances to play the battlefield like a fiddle, letting loose with furious strength or lining up precision attacks against the mightiest foes.
The Maestro Update also introduces two new types of gear, Runes and Crests.
- Runes are a versatile gear type that improves defense stats by giving between 1 and up to a maximum of 5 traits when enhanced, starting at +6 enhancement. Runes are available from the V4 shop.
- Crests are supplemental gear that improve a character’s attack through Crit Hit stats. Rare and better crests provide greater strength by also including defense, PVP, and additional Crit DMG stats. Crests can be found in the Arrogant Plains, Despaired Forest, and Land of Evenfall warzones as well as Lunatra battlefields, which require more than 50,000 CP to enter.
- Both Rune and Crest Enhance Scrolls are required and guarantee up to +2 enhancement, while attempting +3 or higher enhancements may destroy the gear.
To celebrate the arrival of the Maestro, V4 Global players can partake in limited-time reward events including:
- Costume Giveaway Event: All players who log in after the Maestro update, starting March 17, can redeem a free Rare Costume. The “Valiant King” or “Judgement Queen” costumes will be available on the in-game event page, based on the player’s chosen class.
- Red Gem Festival Event: The Red Gem Festival will reward players based on the number of Red Gems they have spent since the V4 Global launch, from July 23, 2020 through March 28, 2021. Using the in-game event page, players who have spent more than 300 gems across all characters will receive rewards according to available exchange tables; players who have spent 299 gems or less will also receive a small reward.
- Amazon Prime Reward Cycles: Starting today, V4 Global players on mobile devices will be able to link their Amazon Prime Account through the in-game menu to receive exclusive rewards once each cycle. Players must link their Amazon Prime accounts during each cycle to receive that cycle’s unique rewards, and the rewards include the Super Starter Pack (containing a 30-day subscription, a Beginner Gear Pack, and a Beginner Accessory Pack) and Rare mounts.
For more information about the all-new V4 Maestro class update, please visit https://www.nexon.com/v4/ or follow @V4Global on Twitter for the latest updates.
Press Assets:
Social: Facebook / Twitter / Instagram / Discord / YouTube
About V4 https://www.nexon.com/v4
Powered by Unreal Engine 4, V4 is a cross-platform free-to-play fantasy MMORPG that gives players the ability to customize their heroes as they defend a breathtaking world from the forces of darkness. With exquisitely detailed battles and offense-focused classes, players can team up with warriors from all over the world on mobile and PC to defeat evil.
About Nexon America Inc. https://www.nexon.com
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005156/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
